Through research on protein networks that control biological systems, Signum is developing therapeutic agents for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. LEARN MORE ABOUT SIGNUM

By targeting PP2A we have discovered a novel approach to developing a new class of molecules to prevent and halt the progression of Alzheimer's disease.
LEARN MORE ABOUT PHOSPHATASE TECHNOLOGY

Signum partners with GlaxoSmithKline (China) Co. Ltd. to advance our proprietary screening technology which targets PP2A. LEARN MORE ABOUT SIGNUM NEWS